Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
Rhea-AI Summary
Nektar Therapeutics (Nasdaq: NKTR) will participate in the 2026 Jefferies Global Healthcare Conference in New York. Management’s fireside chat is scheduled for Wednesday, June 3, 2026 at 1:20 p.m. ET and will be webcast live.
The webcast and 30-day replay will be accessible via Nektar’s investor events webpage.
Positive
- None.
Negative
- None.
News Market Reaction – NKTR
In the May 28 session, NKTR declined 0.60%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | -1.8% | Reported Q1 2026 results with large cash balance and ongoing Phase 3 plans. |
| May 01 | Inducement equity grants | Neutral | +0.5% | Announced stock options and RSUs for six newly hired employees. |
| Apr 28 | Earnings call date | Neutral | -0.7% | Set date and time to release and discuss Q1 2026 financial results. |
| Apr 23 | Public offering closed | Negative | +0.5% | Closed $373.8M underwritten public offering of common stock under S-3ASR. |
| Apr 21 | Public offering priced | Negative | -3.3% | Priced upsized $325M public offering to fund R&D and Phase 3 trials. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: financing and earnings events have produced both aligned and divergent price moves.
Over recent months, Nektar reported Q1 2026 results on May 7, 2026, showing a sizable net loss but backed by substantial cash from prior financings. It also announced inducement equity grants and scheduled its earnings call on April 28, 2026. In late April, the company priced and then closed sizable public offerings at $92.00 per share. Today’s conference-participation news fits a pattern of frequent investor-relations updates alongside capital-raising and earnings disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- 2026 Jefferies Global Healthcare Conference in
New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m. Eastern Time – webcast link here
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the fireside chat will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Contacts
For Investors:
Vivian Wu
628-895-0661
VWu@nektar.com
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
For Media:
Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference-in-new-york-302783711.html
SOURCE Nektar Therapeutics